BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wan JY, Zhang D, Wu XH, Yang H, Dong C. Progress of immune checkpoint inhibitors in gastric cancer. World J Gastrointest Oncol 2025; 17(8): 109613 [PMID: 40837753 DOI: 10.4251/wjgo.v17.i8.109613]
URL: https://www.wjgnet.com/1007-9327/full/v17/i8/109613.htm
Number Citing Articles
1
Xu Lu, Jing Li, Ming-Liang Wang, Hui-Zhen Wang, Yong-Xiang Li. PARVA promotes gastric cancer progression through FBXO15-related PI3K/AKT signaling. World Journal of Gastrointestinal Oncology 2026; 18(10): 121827 doi: 10.4251/wjgo.121827
2
Rui Guo, Meng Gao. Prognostic value of systemic immune-inflammation index in patients with gastric cancer treated with immune checkpoint inhibitors. World Journal of Gastroenterology 2026; 32(34): 119567 doi: 10.3748/wjg.v32.i34.119567
3
Zhouwei Zhan, Ruyu Lin, Yigui Chen, Sha Huang, Luping Lin, Hanchen Zheng, Xiaojie Wang, Xiaoyan Lin, Zengqing Guo, Qiaoting Hu, Bijuan Chen. Plasma immune proteome-based risk score predicts survival in advanced gastric cancer treated with PD-1 inhibitors and chemotherapy. Frontiers in Immunology 2026; 16 doi: 10.3389/fimmu.2025.1715993